Early Antibiotics After Aspiration in ICU Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Early Antibiotics After Aspiration in ICU Patients (NCT05079620), a randomized phase 4 study. The primary outcome is ICU-free Days.

2. Clinical Question

The clinical question concerns whether starting antibiotics soon after suspected aspiration changes subsequent outcomes, rather than waiting to start them unless the clinical picture changes or worsens. The registry describes other outcomes, including ventilator-free, hospital-free, and antibiotic-free days; intubation and tracheostomy after enrollment; pneumonia after enrollment; time before pneumonia criteria were met; and additional antibiotic prescribing. These outcomes provide context for the study’s stated aims, but their results are not reported in the available record.

3. Trial Design

The registry describes a randomized, parallel-group, phase 4 trial with no masking. UConn Health is listed as the sponsor. The study began on 2021-11-30, has a primary completion date of 2024-04-12, and is marked terminated. The recorded enrollment is 5.

The two groups were labeled Antibiotics and Control. The posted primary-outcome results include 2 participants in the Antibiotics group and 3 in the Control group. In the Antibiotics group, treatment was described as 5 days of empiric therapy from a guideline-appropriate regimen. Alternate agents could be selected by the treating team for allergies or other patient factors. In the Control group, there was no initial antibiotic therapy unless the clinical picture changed or worsened. Both groups could receive supportive care, including oxygen and ventilation.

The registry lists five antibiotic agents, but it does not report how often each agent was used or which participants received each one. It also does not give further details about randomization procedures, allocation concealment, or masking beyond the designation of no masking. The method of random sequence generation and any steps to prevent foreknowledge of assignments are not reported in the registry record.

The trial status is recorded as terminated. A reason for termination, the timing of termination, and whether any planned enrollment target was reached are not reported in the registry record. The record does not provide a protocol rationale for the enrollment size or a sample-size justification. These omissions limit what can be concluded about the intended design and the circumstances under which enrollment stopped.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as ICU-free Days, measured over From admission to 30 days, death, or hospital discharge, whichever occurs first.

The primary endpoint, ICU-free days, counts days not spent in the ICU from admission through 30 days, death, or hospital discharge, whichever occurs first. It is reported as a mean with a standard deviation. The registry description notes that both death and discharge can reduce the measure.

This endpoint condenses time in the ICU into a single continuous measure. More days outside the ICU correspond to fewer days spent there during the defined observation period, but interpretation must account for the endpoint’s handling of death and discharge. It is not simply a measure of ICU length of stay among survivors: the registry says that death or discharge can both reduce the measure. Consequently, a mean can reflect more than one clinical course, and the endpoint should be read alongside its definition rather than as a standalone measure of recovery.

The stated timeframe ends at 30 days, death, or hospital discharge, whichever occurs first. The record does not describe how ICU-free days were assigned after death or explain any additional endpoint conventions. Those details are not reported in the registry record. The observed group means and standard deviations describe the posted data; without a reported comparison and information about individual outcomes, they do not establish why the groups differ or whether the difference is attributable to treatment.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

ICU-free days is a continuous outcome, and the registry reports a mean and standard deviation for each group. A mean describes the average observed value; the standard deviation describes how dispersed participant values are around that average. These summaries are useful for describing the posted results, but they do not alone quantify the uncertainty in a treatment comparison. The group sizes are 2 and 3, so the estimates may be strongly affected by the values of individual participants.

What would a treatment-effect estimate add?

A comparative analysis would estimate how the outcome differs between treatment groups and quantify uncertainty around that estimate. A confidence interval is a range calculated by a statistical procedure to show the precision of an estimate under its assumptions. A narrow interval indicates greater precision than a wide interval; an interval that includes values on either side of no difference can reflect uncertainty about the direction and size of an effect. No confidence interval for the primary comparison is reported in the registry record.

A p-value, when reported, describes how compatible the observed data are with a specified statistical null model. It is not the probability that the null hypothesis is true, nor does it measure the clinical importance of an effect. No p-value or inferential primary-outcome analysis is reported. In the absence of those results, the posted means and standard deviations should be treated as descriptive rather than as evidence from a completed statistical comparison.

Why can a comparison be unavailable?

A continuous-outcome comparison generally requires enough information to estimate the contrast and its uncertainty. The registry record indicates that values are missing or not estimable for a two-arm comparison of this continuous endpoint. The posted group summaries remain available, but they are not accompanied by a reported model, test, or uncertainty estimate. The specific reason the comparison was not estimable is not reported in the registry record.

Random allocation is intended to support a fair comparison by assigning participants to groups without choosing treatment based on measured or unmeasured characteristics. It does not guarantee balanced groups in a very small study. With only a few participants, chance imbalances can remain, and observed differences may reflect those imbalances as well as treatment. The registry reports randomized allocation, but details of the sequence-generation and concealment procedures are not reported in the registry record.

How should the planning illustrations be read?

Sample-size planning illustrations based on an observed effect are not the trial’s original design justification. The stated planning assumptions use a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. For continuous outcomes, such illustrations concern participants per arm for a specified power under those assumptions. They are planning scenarios, not observed power and not evidence that the trial was designed to detect those effects. The registry does not report its own sample-size justification.

Planning based on an effect estimated from a very small set of participants can be unstable because the observed effect may be highly sensitive to individual values. Such illustrations are conditional on their assumptions and should not be read as a forecast that a future study will reproduce the observed result. The registry’s stated assumptions do not fill the gap left by a missing comparative estimate.

What do the spread estimates tell the reader?

The reported standard deviations describe variability on the same days scale as the endpoint. Standard deviation is not the same as a confidence interval: it describes variation among observed participants, whereas a confidence interval concerns uncertainty in an estimated quantity. No confidence limits are reported for either group mean. With small groups, neither the standard deviations nor the means provide a stable account of the outcome distribution on their own.

Methods that rely on distributional assumptions may be sensitive to the shape of the outcome distribution, particularly when data are sparse. The registry does not report a model, diagnostics, transformations, or a method for handling unusual values. No alternative analysis is reported. Accordingly, the appropriate statistical reading is limited to the reported descriptive summaries and the absence of a reported comparison.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Antibiotics", "Control")
n   <- c(2, 3)
m   <- c(14, 18.7)
sp  <- c(14.1, 16.1)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Antibiotics  2  14.000  14.100  -112.683  140.683
CARM  Control  3  18.700  16.100  -21.295  58.695

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 16 secondary outcomes in addition to the primary endpoint, including ventilator-free days, hospital-free days, antibiotic-free days, intubation, tracheostomy, pneumonia, time before pneumonia criteria, and additional antibiotic prescribing. The record reports 17 outcome measures overall. It does not provide posted results for these secondary outcomes in the registry record for this analysis, so no secondary-outcome effect estimates or comparisons can be described.

When a study assesses many outcomes, the chance of finding at least one apparently notable result can increase if each is tested separately. Statistical approaches for multiplicity can address that issue, but the registry record does not report whether any adjustment was planned or used. The order of importance among secondary outcomes, any prespecified testing sequence, and any distinction between confirmatory and exploratory analyses are not reported in the registry record.

Information about missing outcome data is also not reported in the registry record. It does not describe the number of participants with missing ICU-free-day data, reasons for missingness, imputation, or sensitivity analyses. The record does not state which analysis population was used, such as whether participants were analyzed according to randomized assignment, nor does it report exclusions after randomization. These details matter because choices about missing data and analysis populations can affect an estimated treatment comparison.

The empty primary-population description and absence of analyses do not establish which participants were intended for each analysis. The record also does not describe interim analyses or stopping rules. Those statistical-plan details are not reported in the registry record. Without this information, the posted summaries cannot be used to assess adherence to a prespecified analysis plan or the possible influence of selective reporting.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event record lists 0 participants with serious adverse events among 2 participants at risk in the Antibiotics group, and 0 among 3 participants at risk in the Control group. It also lists 0 participants with other adverse events among 2 at risk in the Antibiotics group, and 0 among 3 at risk in the Control group. These figures describe the posted counts within each group; the record does not report event terms for serious adverse events.

Deaths are listed separately: 1 in the Antibiotics group and 0 in the Control group. The record does not report the cause of death or establish whether the death was related to treatment. It also does not report timing or other details that would explain the event. The serious-event and other-event counts should not be interpreted as showing that no harm occurred, especially with so few participants and without further event-level information.

These safety counts are descriptive. The registry does not report a comparative safety analysis, uncertainty estimates, or attribution assessments. They therefore cannot establish a difference in safety between groups or explain the relationship between the listed death and the ICU-free-day outcome.

13. What the Result Does, and Does Not, Mean

The registry record documents a randomized comparison of early empiric antibiotics with no initial antibiotic therapy after suspected aspiration in ICU patients. It reports ICU-free-day means and standard deviations for the two groups, along with small group counts. Those descriptive summaries are the primary results available for interpretation in this record.

The results do not establish whether early antibiotics changed ICU-free days. There is no reported treatment-effect estimate, confidence interval, or p-value for the primary endpoint, and the registry indicates that a two-arm continuous-outcome comparison was not estimable. The displayed group means cannot substitute for such an analysis. The record also does not report results for the listed secondary outcomes, so it cannot answer the broader questions about pneumonia, ventilation, hospital-free days, antibiotic-free days, or subsequent antibiotic use.

The small enrollment and group sizes limit precision. Randomized assignment is a design feature, not a guarantee that groups will be comparable when only a few participants are represented. The registry’s terminated status is relevant context, but the reason for termination and intended enrollment target are not reported. It is not possible to determine from this record whether termination affected the results or what the study was expected to establish.

These data should be read as a limited registry record of descriptive outcomes, not as a basis for a treatment recommendation. They do not prove benefit, lack of benefit, or equivalence between strategies. Additional information about the protocol, analysis plan, missing data, participant-level outcomes, and reasons for termination is not reported in the registry record.

14. Why This Trial Matters Statistically

This trial illustrates the difference between a randomized design and a conclusive statistical comparison. Randomization is intended to support causal inference, but the value of that design depends on adequate information and analysis. The registry records enrollment of 5 and posts group summaries based on 2 and 3 participants. Those numbers make the limits of precision central to interpretation.

Means and standard deviations can be reported even when a treatment-effect analysis is unavailable. Readers should distinguish descriptive summaries from a comparative estimate with uncertainty. Here, the registry record reports no inferential analysis of the primary endpoint. That absence prevents a direct statistical assessment of the difference between strategies, regardless of the apparent separation between the posted means.

The endpoint also shows why definitions matter. ICU-free days combine time in the ICU with the registry’s stated handling of death and discharge. A single average cannot reveal which individual pathways produced the group results. The separately reported death count makes clear that mortality is relevant to interpreting this endpoint, while the record does not provide enough detail to connect the death to a specific ICU-free-day value or to treatment.

Finally, the trial’s terminated status, lack of reported sample-size justification, missing comparative analysis, and absent details about missing data and the analysis population demonstrate how registry reporting influences what can be learned. The posted data remain informative as a description of the available record, but they do not answer the causal question with precision. This is an important statistical distinction for clinical researchers reading small randomized studies.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation is the very small recorded enrollment: 5 participants, with posted primary-outcome groups of 2 and 3. Such sparse data allow individual outcomes to have considerable influence on group summaries and provide limited precision. The standard deviations are reported, but no confidence intervals or treatment-effect estimate are available to express uncertainty in the primary comparison.

The study is marked terminated, but the reason and timing of termination are not reported in the registry record. A target enrollment and a sample-size justification are also not reported. It is therefore not possible to assess whether the recorded enrollment was planned, whether it was sufficient for the intended question, or what led to termination.

The registry does not report the statistical analysis for the primary endpoint, and the posted comparison is not estimable under the stated continuous-outcome comparison approach. Information about missing data, analysis populations, exclusions, interim analyses, and multiplicity is not reported. The secondary outcomes are listed, but their results are not available in the record.

The intervention was a regimen selected by the treating team, with alternate agents permitted for allergies or other patient factors. The record does not report which drugs participants received, treatment adherence, or further treatment details. It also does not provide participant-level characteristics, preventing assessment of group balance or clinical heterogeneity. The absence of masking may be relevant to outcomes involving clinical decisions, but the record does not describe assessment procedures. These limitations constrain interpretation without establishing the direction of any bias.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Early Antibiotics After Aspiration in ICU Patients — NCT05079620.
• Registry record last updated 2025-12-30; status last verified 2025-12.
• Results first posted 2025-12-30.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes a randomized, unmasked, parallel-group, phase 4 study of early empiric antibiotics after suspected aspiration in ICU patients. UConn Health is listed as sponsor. The study began on 2021-11-30, has a primary completion date of 2024-04-12, and is marked terminated, with recorded enrollment of 5.

The primary outcome was ICU-free days through 30 days, death, or hospital discharge, whichever occurred first. The Antibiotics group had 2 participants and a mean of 14.0 days with a standard deviation of 14.1. The Control group had 3 participants and a mean of 18.7 days with a standard deviation of 16.1. No primary comparative analysis, confidence interval, or p-value is reported. The registry lists 16 secondary outcomes, but their results are not reported in the record.

Adverse-event counts list no serious or other adverse events in either group; deaths are listed as 1 in the Antibiotics group and 0 in the Control group. Event attribution is not reported. The record does not state the reason for termination, sample-size justification, missing-data methods, or analysis population.